In association with GSK we are republishing this information (first published 29 May 2019) as there remains a lot of uncertainty and confusion in the market, particularly from patients.

A classic example was on Stuff Friday 13th September 2019.

https://www.stuff.co.nz/national/health/115711290/taranaki-man-fearful-drug-funding-change-will-bring-back-a-life-of-seizures

Our industry does not need more of these stories and pharmacy needs to be on the front foot and have discussions now with patients on this medication. We should not assume patients will not wish to stay and pay to remain  on their existing medication.

Further to this, GSK have been in touch with epilepsy patient groups in order that patients (or parents of patients) can be aware that the option of Lamictal is still available privately.

Should you have any questions or require further information please contact GSK customer Service 0800-808-500

Click here to read the notification from GSK relating to the above mentioned product. NSS effective 1 October 2019.

Price change will be implemented where applicable 1 October 2019.

Click here to access the analysis showing the improved profitability by managing to maintain private market.

ProPharma / PWR have prepared an analysis (based on OP Dispensing) to show what the potential cost per month to the patient would be. This analysis is based on an NSS mark up of 25% for the purpose the analysis only. We cannot and will not advise pharmacy on what mark-up they should apply. That is up to each individual. You can also consider STAT dispensing as those rules do not apply to NSS items.

You must be fully aware of the current market activities and your competitors undertaking to provide NSS prescription items at the lowest price to patients. Patients can now have their prescriptions dispensed from outside their home town. So ensure you do not simply allow this market to grow at your cost.

By making this information available now provides adequate time for pharmacy to discuss the change and the option for patients to remain on Lamictal Tablets at a nominal cost.

Providing a choice and letting them make the decision.

Under your existing contract you are required to advise patients of any alternative fully funded options.

We thank you in anticipation of your ongoing support.

About The Author

Close